and recommendation
Cytori Therapeutics, Inc. (CYTX)
Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.
CYTX primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.
CYTX offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.
CYTX also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer.
The company was founded in 1996 and is headquartered in San Diego, California.
- March 24, 2014 - 8:28am | Research Notes
- March 12, 2014 - 7:35am | Earnings Q4
- March 11, 2014 - 10:45pm | Earnings, Earnings Q4
- February 23, 2014 - 3:20pm
- February 4, 2014 - 10:51am | Research Notes
- January 23, 2014 - 9:43am | BOD & C-Suite Updates
- January 15, 2014 - 8:59am | BOD & C-Suite Updates
- January 13, 2014 - 8:54am | Research Notes
- November 21, 2013 - 8:41am | Research Notes
- November 16, 2013 - 6:54pm | Research Notes
- November 7, 2013 - 6:04pm | Earnings
- November 7, 2013 - 12:51pm | Research Notes
- November 4, 2013 - 8:46pm | Research Notes
- October 10, 2013 - 8:46am | IP & Patents
- October 9, 2013 - 8:21am | BOD & C-Suite Updates
- October 7, 2013 - 8:48am | Research Notes
- September 20, 2013 - 9:25am | Research Notes
- September 16, 2013 - 5:49pm | Research Notes
- September 10, 2013 - 9:01am | BOD & C-Suite Updates
- September 6, 2013 - 10:58am | Out and About